Clinical Trials

Phase 1 Active not recruiting

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT03352765 2025-12-04

A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients

28 enrolled

Lymphoma

NCT02996773 2025-11-10

Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine

LymphoidMyeloidOther hematologic neoplasmSarcoma

50 enrolled

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Mycobacterium avium-intracellulare Infection, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

NCT07206264 2025-10-03

ADAPT-MCL

Phase 2 Not yet recruiting

45 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT04083495 2025-09-22

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Phase 2 Recruiting

20 enrolled

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT03039114 2025-08-21

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

26 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence

NCT01974440 2025-05-25

SELENE

Phase 3 Completed

403 enrolled 23 charts

Phase EARLY_PHASE1 Completed

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT03295240 2025-05-13

The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

10 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT01458366 2025-04-30

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide

38 enrolled 17 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT01352312 2025-04-29

Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma

Phase 1 Terminated

10 enrolled

Phase 2 Active not recruiting

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04792489 2025-04-24

DALY II USA/ MB-CART2019.1 for DLBCL

Phase 2 Recruiting

248 enrolled

CNSLymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Lymphoma, Mantle-Cell

NCT01415752 2025-04-08

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

373 enrolled 14 charts

Lymphoma, Lymphoma, Mantle-Cell

NCT03615664 2025-01-16

BURGUND

115 enrolled

Phase 2 Not yet recruiting

Hodgkin Disease, Lymphoma

NCT06557330 2025-01-06

MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma

24 enrolled

Lymphoma

NCT03524235 2024-11-12

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

LymphoidOther hematologic neoplasmPlasma cell

20 enrolled

Hodgkin Disease, Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual

NCT05813132 2024-09-05

BeEAM Versus CEM in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation

Phase NA Completed

58 enrolled

Lymphoma

NCT01716806 2024-06-11

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

131 enrolled 28 charts

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Peripheral

NCT02733042 2023-11-18

FUSION NHL 001

106 enrolled 48 charts

Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04023071 2023-10-26

FT516 in Subjects With Advanced Hematologic Malignancies

Phase 1 Terminated

72 enrolled

Lymphoma, Leukemia, Myeloid, Acute, Lymphoma, B-Cell

NCT04245722 2023-10-26

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Phase 1 Terminated

98 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT01216683 2023-06-29

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

289 enrolled 34 charts

Lymphoma, Lymphoma, Follicular

NCT05899621 2023-06-12

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting

332 enrolled

Lymphoma, Lymphoma, Follicular

NCT02257567 2022-11-14

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

331 enrolled 81 charts 1 FDA

Lymphoma

NCT01412879 2021-10-29

S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

53 enrolled 10 charts

Lymphoma, Lymphoma, Mantle-Cell

NCT02499627 2021-05-27

FIL-BBV

Phase 2 Terminated

43 enrolled

Lymphatic Diseases, Lymphoma

NCT02187133 2021-04-23

Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

10 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence

NCT02059239 2021-02-21

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

34 enrolled 22 charts

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT00389051 2020-10-22

A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma

9 enrolled

Lymphoma, Lymphoma, Non-Hodgkin

NCT01889069 2020-08-13

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)

Phase 3 Completed

159 enrolled 24 charts

Lymphoma

NCT01490723 2020-05-05

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

20 enrolled 9 charts

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00901927 2020-04-03

Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

Phase 2 Terminated

14 enrolled 10 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT00987493 2019-05-15

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma

49 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT01874054 2019-02-12

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

55 enrolled 14 charts

Hematologic Diseases, Hodgkin Disease, Lymphoma

NCT03315520 2018-05-22

BeEAC-1

Phase 2 Unknown

100 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT02130869 2017-12-22

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

8 enrolled

CNSLymphoid

Lymphoma, Neuroblastoma

NCT01234467 2017-05-24

Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma

23 enrolled 16 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT00705250 2017-03-03

Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma

36 enrolled 5 charts

Hodgkin Disease, Lymphoma

NCT01831505 2017-02-27

Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents

4 enrolled